Logo

CERS

Cerus Corporation

CERS

Cerus Corporation • NASDAQ
$1.76 ▲ 0.00% (+0.00)
Market Cap $337.85 M
52w High $2.24
52w Low $1.12
Dividend Yield 0%
P/E -22
Volume 658.06K
Outstanding Shares 191.96M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $52.698M ▲ $26.904M ▼ $-19K ▲ -0.036% ▲ $-0 ▲ $2.566M ▲
Q2-2025 $52.445M ▲ $32.398M ▲ $-5.707M ▲ -10.882% ▲ $-0.03 ▲ $-3.145M ▲
Q1-2025 $43.239M ▼ $31.277M ▲ $-7.717M ▼ -17.847% ▼ $-0.04 ▼ $-5.227M ▼
Q4-2024 $50.809M ▲ $28.834M ▲ $-2.521M ▲ -4.962% ▲ $-0.014 ▲ $-66K ▲
Q3-2024 $46.017M $27.16M $-2.934M -6.376% $-0.016 $-186K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $78.512M ▲ $215.185M ▲ $152.981M ▼ $61.463M ▲
Q2-2025 $78.025M ▼ $213.071M ▲ $156.901M ▲ $55.428M ▼
Q1-2025 $80.919M ▲ $206.776M ▲ $150.534M ▲ $55.492M ▼
Q4-2024 $80.452M ▲ $200.917M ▲ $144.021M ▲ $56.145M ▲
Q3-2024 $75.565M $189.539M $135.258M $53.489M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-19K ▲ $1.927M ▲ $-2.509M ▼ $320K ▲ $-321K ▲ $94K ▲
Q2-2025 $-5.715M ▲ $-2.446M ▼ $-1.089M ▲ $-129K ▼ $-3.454M ▼ $-2.923M ▼
Q1-2025 $-7.718M ▼ $-844K ▼ $-1.189M ▲ $1.071M ▲ $-776K ▲ $-956K ▼
Q4-2024 $-2.562M ▲ $4.929M ▲ $-7.286M ▼ $746K ▲ $-1.848M ▼ $3.953M ▲
Q3-2024 $-2.934M $4.07M $4.817M $60K $9.099M $3.349M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Government Contract
Government Contract
 $10.00M ▲$0 ▼$10.00M ▲$10.00M ▲
Product
Product
 $50.00M ▲$40.00M ▼$50.00M ▲$50.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has been steadily rising over the last several years, showing that demand for Cerus’s blood safety products is growing. The company consistently generates a healthy gross margin, which suggests its core products are priced and produced reasonably well. That said, Cerus still reports accounting losses, although those losses have been shrinking over time. In simple terms, the business is moving in the right direction, with improving profitability, but it is not yet solidly in the black on a net income basis.

Balance Sheet

Balance Sheet Cerus has a relatively lean balance sheet with moderate overall size. It carries a meaningful amount of debt but still maintains a positive equity base, which indicates that assets exceed liabilities. Cash on hand has moved around over the years but does not appear excessive or dangerously low relative to the scale of the business. Overall, the balance sheet looks manageable, but not overly cushioned, so continued discipline around spending and funding will matter.

Cash Flow

Cash Flow The most notable shift is in cash generation: after several years of using cash in its operations, Cerus has recently turned the corner and begun generating positive operating cash flow. Free cash flow has followed the same pattern, improving from negative to positive as the company has held capital spending very low. This means the business is becoming more self‑funding, reducing reliance on outside capital, provided it can sustain or build on this trend.

Competitive Edge

Competitive Edge Cerus operates in a specialized corner of healthcare focused on making blood transfusions safer. Its INTERCEPT Blood System is a flagship technology that inactivates a wide range of pathogens, giving it a clear differentiation from more traditional testing-based approaches. Regulatory approvals in major markets, long-standing relationships with large blood centers such as the American Red Cross, and a portfolio of protected intellectual property together create a sizable barrier for would‑be competitors. Larger companies are active across the broader blood and transfusion landscape, but Cerus holds a particularly strong niche in pathogen reduction for platelets and plasma, which underpins its competitive moat.

Innovation and R&D

Innovation and R&D Innovation is central to Cerus’s strategy. The company continues to enhance its INTERCEPT platform, including newer, more efficient equipment for blood centers. It is also expanding its product line, especially with the INTERCEPT Fibrinogen Complex, which is gaining traction in critical bleeding situations and has attracted interest from defense and emergency-response customers. The most important long-term effort is the red blood cell system, where late-stage clinical results in the U.S. were encouraging, though regulatory progress in Europe has been more challenging. Overall, Cerus is investing actively in R&D to extend its technology to more blood components and new use cases, which could broaden its addressable market if approvals and adoption follow.

Summary

Cerus is a growth-stage medical technology company that has steadily expanded its revenue base and improved its margins, but is still transitioning toward consistent profitability. The balance sheet is adequate but not overly conservative, making continued cash discipline and growth in product adoption important. Recent improvements in operating and free cash flow are a positive sign that the business model is becoming more sustainable. Strategically, Cerus holds a strong, regulation-backed niche in blood safety, supported by proprietary technology and established partnerships. Its future trajectory will largely depend on continued uptake of its current INTERCEPT products, successful commercialization of the red blood cell system, and its ability to maintain financial momentum while funding ongoing innovation.

NEWS

November 6, 2025 · 4:01 PM UTC

Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance

Read more

October 21, 2025 · 8:30 AM UTC

Cerus Corporation Announces Abstracts and Industry Workshop on IFC at the 2025 AABB Annual Meeting

Read more

October 16, 2025 · 4:00 PM UTC

Cerus Corporation to Release Third Quarter 2025 Financial Results on November 6, 2025

Read more